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A 3D-printed nasopharyngeal swab for
COVID-19 diagnostic testing
Jonathan Ford1* , Todd Goldstein2, Sean Trahan2, Allison Neuwirth2, Kyle Tatoris1 and Summer Decker1

Abstract
The nasopharyngeal swab is a critical component of the COVID-19 testing kit. Supply chain remains greatly
impacted by the pandemic. Teams from USF Health Radiology and Northwell Health System developed a 3Dprinted stopgap alternative. This descriptive study details the workflow and provides guidance for hospital-based
3D printing labs to leverage the design to make a positive impact on the pandemic. Swab use is also outlined, and
the early information regarding clinical use is described, including an ongoing multicenter trial methodology.
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Introduction
The World Health Organization designated COVID-19 a
global pandemic on March 11, 2020. In addition to the
physical mortality and morbidity on patients, the disruption due to this widespread disease has also effected global supply chain of critically needed medical supplies.
Medical supply shortages included ventilators, respirators, masks, face-shields, and various other PPE [1]. 3D
printing is an effective stopgap technology for medical
devices and additional supplies [2]. There is an international shortage of the synthetic flocked nasopharyngeal (NP) swab which combined with virial transport
media in a test tube completes the COVID-19 testing kit
[3]. This shortage contributed to deficiencies in testing
in the United States.
At this time, the Division of 3D Clinical Applications
at the University of South Florida’s (USF) Department of
Radiology began looking into the potential for creating a
3D printed alternative for the traditional flocked, NP
swab. Using materials that are commonly used in their
everyday clinical printing work that were FDA approved
for biocompatibility, they were able to come up with a
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single part design. The printer selection was based on
prior FDA approval, available materials and the knowledge that the printer was widely available across the
country in many hospitals. Working with colleagues in
USF Health Infectious Disease, Otolaryngology and a
radiologist, they were able to narrow down the designs
to one that would be able to capture a sufficient sample
for COVID testing while keeping patient safety and
comfort at the forefront. Working with the 3D Design
and Innovation lab at Northwell Health, they were able
to come up with a design for bench lab testing all in less
than a week. Bench lab testing was completed within a
couple of days and results immediately demonstrated
that the printed swabs were in fact able to detect viral
loads and hold those values for 24 h to over 3 days. In
light of the bench lab results, a multisite clinical trial
was started at Tampa General Hospital (USF Health’s
teaching hospital) in order to determine the swab’s clinical efficacy. The clinical trial first tested the traditional
swab against the 3D printed swab in known COVID
positive patients and later tested in tandem in patients
presenting to the emergency rooms. The results showed
that the printed swab performed as well as and, in some
cases, better than the traditional swab. Early results of
the trial from Northwell Health and Tampa General
Hospital were presented to the hospital review

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.

Ford et al. 3D Printing in Medicine

(2020) 6:21

committees where the 3D printed NP swabs were approved to be the standard of care swab in light of the
supply shortage. [Press Release].
As part of the design process, USF Health filed and
received a provisional patent [4] on the 3DP NP swab
design and concept. The intent was to share the project files for free to appropriate parties like hospitals,
clinics, and medical device manufacturers so that any
site throughout the world with 3D printing capabilities could use the technology to address these swab
shortages. The team specifically approached members
of the RSNA 3D Printing Special Interest Group who
are trained and approved medical print teams with
the designs so that they could help their hospitals.
They also joined with FormLabs, the printer manufacturer, in an effort to work with industry for assistance
in printing swabs for groups and agencies that were
beyond their legal boundaries. Their printers, the
Form 2 and Form 3B became the first printers that
the NP swabs were printed on nationally.
While USF Health and Northwell Health were the first
to test and release the 3DP NP swabs, subsequently numerous other printer companies began working in this
area. Several other institutions have tested 3DP alternatives for the swab shortage. For example, Beth Israel
Deaconess Medical Center (BIDMC) conducted a robust
study examining 160 designs from 48 different materials
from 48 different manufacturers, focusing on four designs in a clinical trial [5]. The BIDMC study increases
the printer options for manufacturing 3DP swabs, but
the machines used are not as ubiquitous as the Form 2
or Form 3B.
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To date, there are millions of the USF Health – Northwell Health designed 3D printed NP swab that are actively being produced and used by health care
institutions around the US and world.
This paper describes the collaboration between the USF
Health and Northwell Health to develop a 3D-printed
(3DP) alternative NP swab. Roles and responsibilities of
each partner are described. The role of testing is outlined,
as is the methodology for a multi-center clinical trial.

Materials and methods
Swab design and development

Swabs were printed using Formlabs Form 2 and Form
3B SLA 3D-printers because - in combination with FDA
cleared software, they were considered readily available
with biocompatible materials and relatively affordable
for local deployment.
Initial prototype computer-aided design (CAD) designs
used Solidworks (France), 3-matic (Belgium) or Fusion 360
(United States). Over twenty tip designs were prototyped,
some early examples can be seen in Fig. 1. The goal of tip
design was to maximize surface area, sample retention
and comfort. Prototypes were narrowed down by clinicians from radiology, infectious disease and otolaryngology. After several design modifications were requested
and completed, a final design consisting roughly of a 150
mm in total length with a 70 mm breakpoint. The tip
length is 15 mm long, with a diameter of 3.85 mm. The tip
has a rounded nose for patient comfort. The neck is 1.5
mm in diameter and the shaft is 2.45 mm in diameter.
The base is 1.75 mm long with a 5 mm diameter (Fig. 2).
As each 3DP swab utilizes approximately 0.76 ml of resin

Fig. 1 Early alternate 3DP swab designs. Letter C is the current version in use
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Fig. 2 Computer-assisted Drawing (CAD) of NP Swab

to print (when combined with post-processing materials
and potential waste), each swab costs approximately $0.25
USD to print. “Tip C” is the current tip configuration that
is in use presently. “Tip D” is an experimental swab designed for smaller nasal passages made at the request of
our clinicians.
Bench lab testing of the final swab designs was conducted to ensure the geometries picked up enough of a
sample to allow for viral testing. Swab materials were incubated for up to 3 days to ensure the printer resin
would not interfere with downstream viral testing. As
viral transport media (VTM) is also potentially in short
supply, additional testing was used utilizing in house
mixing of VTM using the World Health Organization
recipe [6].
Current algorithm for swab printing

The STL of the 3DP swab was then arrayed for 3Dprinting using the Preform software. A balance of printing the most swabs and limiting the contact points to
avoid any potential issues determined that 324–380
swabs could be safely printed per batch (Fig. 3). Swabs
are printed at a layer thickness of 100 μm (the fastest
setting) using Surgical Guide version 1 resin, with the

Fig. 3 Four batches of 324 3DP NP swans ready for post-processing

base directly in contact with the platform with no rafts
and no supports.
3DP swabs are rinsed using a Form Wash for 20 min
in 99% isopropyl alcohol. This washing process is performed while the swabs are still attached to the build
plate. Manual washing may be possible using the Finishing Kit, however swabs would need to be removed from
the platform first. Once the wash is complete, the prints
are allowed to airdry for at least 30 min. Afterwards the
swabs are gently scraped off the build platform. The placing of a loose rubber band around the printed swabs
prior to scraping them from the platform assisted in
overall organization (Fig. 4).
The swabs are then suspended from the base (with the
tip pointing down) in a curing rack and placed in the
Form Cure for 60 °C for 30 min (Form 2) or 70 °C for 30
min (Form 3B). An example of a curing rack can be seen
in Fig. 5. The inverted suspension of the NP swabs by a
rack during curing removed issues with bent necks or
shafts. It is recommended that the curing rack not be
overcrowded to ensure that enough airflow and UV exposure occurs for each swab. Once the curing is
complete, 3DP swabs are placed in steam sterilization
pouches, and prepared for sterilization. Pre-vacuum
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Fig. 4 Example of a loose rubber-band (elastic) to assist in swab removal from platform

steam sterilization cycle set at 132 °C/270 °F with a 4 min
sterilization phase and 30 min dry is an appropriate
sterilization cycle. Additionally, swabs may be treated in
Prolystica 2X Enzymatic Presoak and Cleaner prior to
pouching.
Several differences were also noted between the Form
2 and Form 3B. Form 2 s printed at 15–16 h per batch.
Form 3Bs initially printed between 26 and 36 per batch.
However, firmware updates and software settings have
lowered print times to 10–11 h. Form 3Bs also have
greater reject rates with some swabs failing to adhere to
the build platform as well as higher rates of print inconsistencies with a “jittery” effect noted (Fig. 6).
There are several considerations for those planning to
utilize this workflow. The Surgical Guide resin is a
photo-reactive polymer. Once the swabs have been

Fig. 5 a: Top, b: Side and c: Three-Quarter View of Curing Rack

sterilized, they should be kept out of direct light prior to
use to prevent them from becoming more brittle over
time. Storing them in a dark location prior to use would
increase shelf-life. Additionally, isopropyl alcohol of 99%
is critical to the washing cycle and due to high market
demands, be sure it can be acquired readily.

Discussion
Implementation of swab in practice

At USF Health, 3DP swabs are produced and postprocessed (washed and cured) prior to being sent for
sterilization. The swabs are individual packaged and
autoclaved then are bundled with the test tube and
VTM to complete the COVID-19 testing kit. These kits
are then provided to the testing sites for use. Once the
samples are collected, the swabs are broken off into a
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Fig. 6 Example of “jittery” failed swab

test tube containing VTM and then PCR analysis is run
in our diagnostic laboratories.
Several meetings have been held with the US Food
and Drug Administration (FDA) with respect to the
usage of 3DP swabs. The 3DP swabs have been declared
a Class 1 exempt medical device and is subject to the
least amount of regulatory control. Potential users
should closely follow any relevant FDA, NIH, and VA
announcements and advisories in regard its use and testing capabilities. There are restrictions on who can legally
print and provide 3DP swabs. Hospitals and health care

facilities can produce their own swabs and provide them
for their own in-house use and to their affiliate sites. Licensed medical device manufacturers may also produce
3DP nasopharyngeal swabs. It is advised that any parties
seek legal counsel to ensure they are within their legal
bounds prior to attempting to print the swabs. At the
time of submission for publication, USF Health and
Northwell Health combined have produced several
hundred-thousand swabs. Across the globe in a variety
of institutions and countries the current estimate is that
25 million swabs have been produced.
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At the USF Health and Northwell Health facilities,
3DP swabs are being assembled as part of a test kit. Internal laboratories at each respective hospital are collecting patient samples and testing them in-house. As of the
time of this publication, two of the leading medical testing services, LabCorp and Quest Diagnostics, are waiting
for an official statement from the FDA prior to accepting
the 3DP swab.
Clinical effectiveness

USF Health/Tampa General Hospital (TGH) started a
multisite clinical trial that is currently underway. This
trial is testing the 3DP swab against the current synthetic version. USF Health/TGH as well as Northwell
Health are conducting head-to-head trials utilizing each
swab on the same patient in alternate nostrils. Study
participants include any patients suspected of COVID19 or current patients in the hospital with a known
COVID-19 diagnosis. The initial results at both USF
Health/TGH and Northwell Health show a 94% concurrence with no statistical differences between the threshold cycle (Ct) values when comparing the 3DP swab
against the synthetic swab. Both hospitals have concluded that the 3DP swab is a viable alternative to the
synthetic swab and are now using them as their standard
of care swab. Several other sites participating in the clinical trial are in different stages of completion. A full publication and study will be published upon the conclusion
of the trial.
Impact

The response and impact of the USF Health – Northwell
Health 3DP NP swab has been tremendous. While the
clinical trials are ongoing at many sites, numerous states
around the US including New York, Florida, Massachusetts, Kansas, Oklahoma, Virginia, and Ohio all have
been using the design at the state level with Ohio having
over 1 million alone. Additionally, all branches of the US
military have been working with the USF Health and
FormLabs teams to develop the design for COVID testing within the military. The swab has also expanded
internationally to Canada, Colombia, Brazil, Japan,
Switzerland, Argentina, Malaysia, Georgia, the
Philippines, and the United Kingdom. The invention has
been featured in the media, like Forbes and the Wall
Street Journal, nationally and internationally as an example of the power of medical 3D printing and quick
innovation for clinical solutions.

Conclusion
3D printed nasopharyngeal swabs provide a costefficient and fast alternative to the standard NP swabs
used for COVID-19 testing kits. As members of the
Radiological Society of North America’s 3D Printing
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Special Interest group [7], this project was initiated
and developed through collaborations established in
the 3D SIG.
Point-of-care or in hospital 3D printing is uniquely positioned to understand the immediate needs of a hospital
and act on them quickly. By working together between
hospitals and industry during the pandemic, valuable
time was saved to address the shortage needs in our respective hospitals. The in-house production of these
3DP swabs alleviated this major supply chain hurdle and
directly increased testing capabilities at USF Health,
Tampa General Hospital and Northwell Health System.
Today there are millions of 3D printed nasal swabs
around the world demonstrating the field of 3D printing’s ability to address the supply shortages of critical
need resources used for COVID testing.
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